2018 Webinar: HBV - Update on the Guidelines and Controversies in Management
Recorded On: 10/24/2018
This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk. The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.
Naga P. Chalasani (Moderator)
Naga P. Chalasani, MD, FAASLD currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine. He previously served as the Director of the Division of Gastroenterology and Hepatology at the same institution from 2007 to 2020. He completed his medical education in India and subsequently completed Internal Medicine Residency and Gastroenterology and Hepatology subspecialty training at Emory University in Atlanta. His research interests include CYP450 enzymes and liver disease and hepatic safety of xenobiotics. His research has been continuously funded by the National Institutes of Health since 1999. He is currently the PI for three U01 awards and an R01 award from the National Institutes of Health. He published over 300 original papers, 3 Practice Guidelines, 47 book chapters/review articles, 31 editorials/commentaries, 16 symposium proceedings, and more than 500 abstracts. He is the lead author for the AASLD Practice Guideline on the Diagnosis and Management of Nonalcoholic Fatty Liver Disease and is the lead author on the ACG Practice Guideline on the Diagnosis and Management of Drug Induced Liver Injury. He is an elected member of the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP).
Mark W. Russo
Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. At the American Association for the Study of Liver Diseases, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine. He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.
Dr. Kosh Agarwal is a Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies, King’s College Hospital. Dr Agarwal is the Lead for the Kings Viral Hepatitis Service, the largest treatment centre for viral hepatitis in the UK. In 1991 Dr Agarwal graduated from Newcastle University and his postgraduate training was undertaken in Newcastle with the majority of his clinical and research training at the Regional Liver and Transplant Unit. Prior to his appointment at King’s, Dr Agarwal was a consultant and honorary senior lecturer at the Regional Liver and Transplant Unit in Newcastle. He also spent a year at the Division of Liver Diseases, Mount Sinai, New York, USA. Dr Agarwal is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic Hepatitis B and C. He is a member of the EASL, AASLD, BASL, & ILTS.